Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide as Second Line Therapy in Chronic GVHD
NCT00675441Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate at 180 days and Safety and Tolerability at 1 year. Started Apr 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00675441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00675441.